1. Dear Drugs-Forum readers: We are a small non-profit that runs one of the most read drug information & addiction help websites in the world. We serve over 4 million readers per month, and have costs like all popular websites: servers, hosting, licenses and software. To protect our independence we do not run ads. We take no government funds. We run on donations which average $25. If everyone reading this would donate $5 then this fund raiser would be done in an hour. If Drugs-Forum is useful to you, take one minute to keep it online another year by donating whatever you can today. Donations are currently not sufficient to pay our bills and keep the site up. Your help is most welcome. Thank you.
    PLEASE HELP

First-Ever Protective Effect Is Small but Suggests HIV Vaccine Is Possible

By whitenoise, Sep 25, 2009 | Updated: Sep 25, 2009 | | |
Tags:
Rating:
4/5,
  1. whitenoise
    AIDS Vaccine Success Is 'Modest'
    First-Ever Protective Effect Is Small but Suggests HIV Vaccine Is Possible
    By Daniel J. DeNoon
    WebMD Health News
    Reviewed by Louise Chang, MD

    Sept. 24, 2009 - "Modest" success in an HIV vaccine trial shows for the first time that vaccination can protect people against infection with the AIDS virus.

    It's a small but significant step forward. Few, if any, think this vaccine is effective enough to deploy in the worldwide fight against AIDS. But many experts say it offers badly needed hope to an effort marked by many expensive failures.

    "While these results are encouraging, we recognize that further study is required to build upon these findings," Col. Nelson Michael, director of the U.S. Military HIV Research Program, says in a news release.

    The trial was a collaboration between the U.S. Army, Thailand, the U.S. National Institute of Allergy and Infectious Diseases, Sanofi Pasteur, and Global Solutions for Infectious Diseases. It tested Sanofi's ALVAC vaccine boosted with a dose of GSID's AIDSVAX.

    Conducted in Thailand, it began in 2003 and enrolled 16,402 adult, HIV-negative men and women. Half got the two-part vaccine, and half got inactive placebo shots.

    Over the course of the study, 74 placebo recipients and 51 vaccine recipients became infected with HIV. The difference isn't large, but it translates into 31% vaccine effectiveness. That is, it lowered the risk of getting HIV by 31%.

    That's "an important step forward in HIV vaccine research," NIAID director and long-time AIDS researcher Anthony Fauci, MD, says in a news release. "Certainly this is an encouraging advance."

    Even so, the study results are puzzling. It was expected that vaccine recipients who became infected would at least have some protection against the virus. But the study found no evidence of such protection. HIV levels were just as high in vaccine recipients who became infected as in placebo recipients who contracted the virus.

    Perhaps more importantly, the study fell far short of its goal of reducing the risk of HIV infection by 50%.

    The study was controversial from the outset. It's the largest HIV vaccine trial yet conducted, and some AIDS activists called the study a waste of precious resources.

    AIDSVAX, the first HIV vaccine ever to be tested, had already failed to prevent HIV in a number of trials. ALVAC, a live canarypox virus carrying HIV genes, did not appear to stimulate strong immune responses in healthy people. And similar combination vaccine strategies showed little evidence of eliciting strong immune responses.

    Moreover, a similar study of the ALVAC and AIDSVAX vaccines had been canceled in the U.S. And critics said the study design would make it hard to tell which part of the vaccine regimen was or was not effective.

    Now that the study is completed, researchers will go over the data with a fine-tooth comb. They'll try to figure out what worked and build on that success.

    "Knowledge gained through this study will be used to accelerate future study design and testing as researchers continue the search for a safe, globally effective HIV vaccine," Col. Jerome Kim, HIV vaccines product manager for the U.S. Army, says in a news release.

    By Daniel J. DeNoon
    WebMD Health News
    Reviewed by Louise Chang, MD
    Link can be found below in a post by
    chillinwill bellow

Comments

  1. whitenoise
    I wanted to post the link to the article but I do not have 50 posts yest so it will not allow me to.
  2. chillinwill
    The link can be found Here


    Please note that the way we post news has changed, because of our main news page. You can find the full instructions here.

    The most important changes are:

    • Articles are no longer posted in quotes.
    • The introduction of the article should be in bold.
    • Images should be added if possible and placed in the article, following the instructions linked to above and here.
    • Information about the article, like link, author, date should be posted below the article.
    • Your personal comments about the article can be posted either in quotes at the end of the article or in a separate post.
    • The news forums may contain news articles only
    • Make sure you include all the text from the original article. Don't just post the URL because web pages often disappear or get moved over time. Remove all unnecessary formatting from the text before posting. One easy way to do this is to paste the text into notepad or another text editor first, which will remove any formatting. Also try to remove picture captions, advertisement links and other text that doesn't belong to the body of the article.

    Please be so kind to review your articles and correct this.

    Further it may be good to know that recent articles with the highest thread ratings show up on the main news page. So without ratings, many people will not see it. So please rate news treads.
    The main news page is accessible from the tabs on the top of any DF page.
To make a comment simply sign up and become a member!